Loading...
Loading...
Exelixis
EXEL today announced interim data from 51
patients with metastatic castration-resistant prostate cancer (CRPC) and
bone metastases receiving a 40 mg daily dose of cabozantinib in an
ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized
discontinuation trial. The data suggest that the 40 mg daily dose has
similar clinical activity to the 100 mg daily dose previously reported
from this trial for key parameters, including reduction of metastatic
bone and soft tissue disease, and reduction of bone-related pain and
narcotic use, with apparent improvement in adverse event rates and
tolerability. Johann de Bono, M.D., Ph.D., leader of the prostate cancer
targeted therapy team at The Institute of Cancer Research, London, and
honorary consultant at The
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in